MOLECULAR BASIS OF CONGENITAL THYROTROPIN DEFICIENCY
先天性促甲状腺激素缺乏症的分子基础
基本信息
- 批准号:6189892
- 负责人:
- 金额:$ 7.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2000
- 资助国家:美国
- 起止时间:2000-07-06 至 2002-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (Adapted from applicant's description): Congenital hypothyroidism
(CH) is one of the most common causes of preventable mental and growth
retardation, with a collective incidence of 1:3-4,000 births. Early diagnosis
and treatment is critical to the prevention of life-long debility because
there is an inverse relationship between the age at which treatment is
initiated and eventual psychometric outcomes. Thyroid hormone acts globally to
activate metabolism and is required for normal growth and neonatal development
of the brain and immune system. Thyroid hormone secretion is a finely
regulated process that depends on a hormone cascade of the hypothalamus,
pituitary gland, and thyroid gland. Though less common, CH due to pituitary
defects present a particular diagnostic challenge to neonatal screening
programs, resulting in delay of treatment. There has been no animal model of
pituitary CH from which one might gain insight into such issues as the loss of
thyrotropin-releasing hormone (TRH)-mediated functions in organs other than
the pituitary gland. An inherited form of CH resulting in disproportionate
growth delay, male hypofertility, and behavioral abnormalities was identified
in a canine family. TRH-stimulation testing and hormone analysis demonstrated
that the disorder is caused by failure of the pituitary gland to increase
thyrotropin (TSH) secretion appropriately in affected dogs in spite of low
thyroid hormone concentrations. The longterm goals of this investigation are
to characterize and use this unique animal model of human CH to better
understand normal pituitary function, non-thyroid gland-mediated functions of
thyrotropin, and the pathogenesis of deficient TRH signaling. Immediately the
investigators proposed to determine the molecular basis of the disorder in
order to give added significance to future studies of pathogenesis. The
specific aims of this proposal are: 1) to maintain a breeding colony of CH
dogs and to perform matings which extend the CH family in a way that is most
informative for candidate gene linkage studies, 2) to examine the TRH-mediated
signal transduction pathway of TSH secretion by measuring TRHstimulated
calcium ion currents in affected and normal dog cells in order to generate
candidate gene hypotheses, and 3) to investigate the molecular basis of canine
CH by examining candidate disease genes. Initial emphasis will be analysis of
the candidate gene encoding the TRH receptor.
描述(改编自申请人的描述):先天性甲状腺功能减退症
(CH)是可预防的精神和成长的最常见的原因之一
发育迟缓,集体发病率为1:3- 4 000。早期诊断
治疗对于预防终身衰弱至关重要,
在治疗的年龄之间存在反比关系,
开始和最终的心理测量结果。甲状腺激素在全球范围内发挥作用,
激活新陈代谢,是正常生长和新生儿发育所必需的
大脑和免疫系统。甲状腺激素的分泌是一种精细的
调节过程依赖于下丘脑的激素级联,
脑下垂体和甲状腺。虽然不太常见,但由于垂体
缺陷对新生儿筛查提出了特殊的诊断挑战
方案,导致治疗延误。目前还没有动物模型
垂体CH,从中人们可以深入了解这些问题,
促甲状腺激素释放激素(TRH)介导的器官功能,
脑下垂体一种遗传形式的CH,导致不成比例的
发现了生长迟缓、男性生育力低下和行为异常
在一个犬科家庭里TRH刺激试验和激素分析表明,
这种疾病是由脑垂体无法增加
促甲状腺激素(TSH)分泌适当的受影响的狗,尽管低
甲状腺激素浓度这项调查的长期目标是
为了表征和使用这种独特的人类CH动物模型,
了解正常垂体功能,非甲状腺介导的功能,
促甲状腺激素和TRH信号传导缺陷的发病机制。立即
研究人员建议确定这种疾病的分子基础,
以期为今后的发病机制研究提供更多的意义。的
这项建议的具体目标是:1)维持一个CH的繁殖群体
狗和执行交配,扩大CH家庭的方式,是最
为候选基因连锁研究提供信息,2)检查TRH介导的
促甲状腺激素分泌信号转导途径的研究
受影响的和正常的狗细胞中的钙离子电流,以产生
候选基因假说,3)研究犬的分子基础,
CH通过检查候选疾病基因。最初的重点将是分析
编码TRH受体的候选基因。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN C FYFE其他文献
JOHN C FYFE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN C FYFE', 18)}}的其他基金
CONGENITAL HYPOTHYROIDISM IN GIANT SCHNAUZERS
巨型雪纳瑞的先天性甲状腺功能减退症
- 批准号:
7391959 - 财政年份:2006
- 资助金额:
$ 7.4万 - 项目类别:
CONGENITAL HYPOTHYROIDISM IN GIANT SCHNAUZERS
巨型雪纳瑞的先天性甲状腺功能减退症
- 批准号:
7153996 - 财政年份:2005
- 资助金额:
$ 7.4万 - 项目类别:
CONGENITAL HYPOTHYROIDISM IN GIANT SCHNAUZERS
巨型雪纳瑞的先天性甲状腺功能减退症
- 批准号:
7011854 - 财政年份:2004
- 资助金额:
$ 7.4万 - 项目类别:
Molecular Mechanism of Polarized Cubilin Expression
极化Cubilin表达的分子机制
- 批准号:
6732074 - 财政年份:2003
- 资助金额:
$ 7.4万 - 项目类别:
Molecular Mechanism of Polarized Cubilin Expression
极化Cubilin表达的分子机制
- 批准号:
6598635 - 财政年份:2003
- 资助金额:
$ 7.4万 - 项目类别:
MOLECULAR PATHOGENESIS OF FELINE SPINAL MUSCULAR ATROPHY
猫脊髓性肌萎缩症的分子发病机制
- 批准号:
6233658 - 财政年份:2001
- 资助金额:
$ 7.4万 - 项目类别:
MOLECULAR PATHOGENESIS OF FELINE SPINAL MUSCULAR ATROPHY
猫脊髓性肌萎缩症的分子发病机制
- 批准号:
6530558 - 财政年份:2001
- 资助金额:
$ 7.4万 - 项目类别:
相似海外基金
The pathogenesis of ALG14-congenital disorders of glycosylation.
ALG14-先天性糖基化障碍的发病机制。
- 批准号:
23K14967 - 财政年份:2023
- 资助金额:
$ 7.4万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Identifying New Therapeutics and Molecular Mechanisms in Congenital Disorders of Glycosylation.
确定先天性糖基化疾病的新疗法和分子机制。
- 批准号:
10644811 - 财政年份:2023
- 资助金额:
$ 7.4万 - 项目类别:
Investigating the Genotype-Phenotype Relationships that Underlie Congenital Disorders with Cardiovascular Symptoms through Population-scale Analyses
通过人群规模分析研究具有心血管症状的先天性疾病背后的基因型-表型关系
- 批准号:
10724185 - 财政年份:2023
- 资助金额:
$ 7.4万 - 项目类别:
Identifying understudied protein-related glycoproteome disruption in Congenital Disorders of Glycosylation
识别先天性糖基化障碍中尚未研究的蛋白质相关糖蛋白组破坏
- 批准号:
10725869 - 财政年份:2023
- 资助金额:
$ 7.4万 - 项目类别:
Pathogenic Mechanisms of Congenital Disorders of Glycosylation
先天性糖基化障碍的发病机制
- 批准号:
10633548 - 财政年份:2023
- 资助金额:
$ 7.4万 - 项目类别:
Assessment of a potential application of endogenous stem cells to treat congenital disorders
评估内源干细胞治疗先天性疾病的潜在应用
- 批准号:
22K20740 - 财政年份:2022
- 资助金额:
$ 7.4万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Targeting aldose reductase: A Phase IIb/III trial for the novel use of Epalrestat to treat Congenital Disorders of Glycosylation (PMM2-CDG)
靶向醛糖还原酶:依帕司他新用途治疗先天性糖基化障碍 (PMM2-CDG) 的 IIb/III 期试验
- 批准号:
10480649 - 财政年份:2022
- 资助金额:
$ 7.4万 - 项目类别:
Targeting aldose reductase: A Phase IIb/III trial for the novel use of Epalrestat to treat Congenital Disorders of Glycosylation (PMM2-CDG)
靶向醛糖还原酶:依帕司他新用途治疗先天性糖基化障碍 (PMM2-CDG) 的 IIb/III 期试验
- 批准号:
10616658 - 财政年份:2022
- 资助金额:
$ 7.4万 - 项目类别:
O-glycosylation mechanisms of neurological deficits in congenital disorders of glycosylation
先天性糖基化障碍神经功能缺损的O-糖基化机制
- 批准号:
10040788 - 财政年份:2020
- 资助金额:
$ 7.4万 - 项目类别:
O-glycosylation mechanisms of neurological deficits in congenital disorders of glycosylation
先天性糖基化障碍神经功能缺损的O-糖基化机制
- 批准号:
10250486 - 财政年份:2020
- 资助金额:
$ 7.4万 - 项目类别:














{{item.name}}会员




